• News | Posted on October 23, 2017

CPS is the first in nation to offer the new next generation Medtronic Spinal Cord Stimulator for long-term management of chronic pain

Brentwood, Tenn. – [Oct. 13, 2017] – Comprehensive Pain Specialists (CPS) is the first and only in the country to offer the Intellis™ platform, including the world’s smallest implantable spinal cord stimulator (SCS) for the management of certain types of chronic intractable pain.

Chronic pain is a debilitating condition that can negatively impact all aspects of a person’s life – relationships, work productivity and activities of daily living, yet it remains under-recognized and undertreated.1 Given the national crisis involving opioid abuse, it’s more important than ever for patients suffering from chronic pain to have access to new non-opioid treatment options.

“At CPS, we are part of the solution,” says Dr. Peter Kroll, chief executive officer and chief medical officer. “We believe in responsible medication management and interventional modalities. There is no ‘one-size-fits-all’ approach to managing pain. It’s more important than ever for CPS to offer an effective, long-term, non-opioid solution; the availability of the Intellis spinal cord stimulator should offer new hope to patients struggling with debilitating pain.”

Back problems are one of the top 10 most expensive medical conditions, with an estimated 30 percent of the 300,000 patients annually that undergo lumbosacral spine procedures developing chronic intractable pain.1 Medtronic neurostimulation therapy for chronic pain uses an SCS system, which is a medical device placed under a patient’s skin to deliver mild electrical impulses through a lead implanted in the epidural space to block pain signals from going to the brain. Neurostimulation has been proven to provide effective long-term pain relief and improve quality of life, in addition to being a treatment option for patients interested in trying a non-drug alternative.2-6

About CPS

Comprehensive Pain Specialists was founded in 2005 with a vision of experienced physicians and staff dedicated to identifying and treating all types of pain. CPS has 54 locations in 10 states, boasts a research department with a combined 200 years of experience in clinical research in the specialty of pain management. For more information, visit or

About the Intellis ™ Platform

The Intellis™ platform includes the world’s smallest implantable SCS neurostimulator and offers important patient benefits, including optimizing treatment and improving patient-physician communication by tracking and sharing daily activities, body positions and therapy usage and giving physicians an objective look at mobility and progress. The system also addresses a common patient complaint: the daily or weekly recharge burden. With Medtronic’s proprietary Overdrive™ battery technology, the Intellis platform can be fully recharged from empty to full in approximately one hour and is optimized for meeting the energy demands of high-dose (HD) therapy options offered in the Evolve SM Workflow.*

* A workflow is guidance only and physicians should use their medical judgment and product labeling to optimize therapy for individual patients, which may require discontinuation or modification of a workflow.

The ability to utilize MRI diagnostic imaging is limited with most SCS systems, but the Intellis platform allows the broadest access to this important diagnostic tool.† This is significant because studies show approximately 82 percent of patients implanted with an SCS system are expected to need an MRI within five years of receiving the implant.7 The Intellis platform also has AdaptiveStimTM technology which automatically adjusts to deliver the right dose to the right location, as the pain target shifts based on body position.


  1. Mekhail N, Wentzel DL, Freeman R, Quadri H. Counting the costs: case management implications of spinal cord stimulation treatment for failed back surgery syndrome. Prof Case Manag. 2011;16(1):27-36.
  2. North RB., Kidd DH., Farrokhi F, et al. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurg; 56: 98–106 (2005).
  3. Kumar K., Taylor RS., Jacques L, et al., Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicenter randomised controlled trial in patients with failed back surgery syndrome. Pain; 132: 179–188. (2007).
  4. Kemler MA., De Vet HCW., Barendse GAM et al., The effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years’ follow-up of the randomized controlled trial. Ann Neurol; 55: 13–18 (2004).
  5. Taylor RS, Spinal cord stimulation in Complex Regional Pain Syndrome and Refractory Neuropathic Back and Leg Pain/Failed Back Surgery Syndrome: results of a systematic review and meta-analysis. J Pain Symptom Manage; 31: S13–S19 (2006).
  6. Cameron T, Safety and efficacy of spinal cord stimulation for the treatment of chronic pain – a 20 year literature review. J Neurosurg Spine; 100: 254–267 (2004).
  7. Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015 May 1;40(9):E531-7.


Advanced Therapy for Cancer Pain

  • News | Posted on July 6, 2013